Comparing the Efficacy and Safety of High-Intensity Statins in Patients with Cardiovascular Disease: Insights from the LODESTAR Secondary Analysis Study
Professor Lee Yong-jun, Yonsei University School of Medicine Stronger LDL cholesterol (LDL-C) targets are recommended than before for patients at very high risk of cardiovascular disease, i.e. patients with dyslipidemia accompanied by coronary artery disease (CAD). As a result, the prescriptive position of high-intensity statins, which have been shown to have excellent effects in reducing […]
Comparing Statin Strategies for Cardiovascular Disease Prevention: LODESTAR Study Findings
Professor Hong Seong-jin of Yonsei University School of Medicine A national randomized controlled trial (RCT) comparing the efficacy and safety of two representative statin strategies in terms of secondary prevention of cardiovascular disease in patients with dyslipidemia was published last year in JAMA, the official journal of the American Medical Association, and attracted attention. In […]
Statins Recommended for Cardiovascular Disease Prevention in People with HIV: New Guidelines
▲Image source: Getty Image Bank. [메디칼업저버 박선혜 기자] The U.S. Department of Health and Human Services (HHS) has recommended statins as a treatment for the primary prevention of cardiovascular disease in people infected with the human immunodeficiency virus (HIV). In the phase 3 REPRIEVE clinical trial announced last year, pitavastatin was found to significantly reduce […]
The Role of Rosuvastatin in the Prevention and Treatment of Cardiovascular Disease
Professor Kim Shin-gon, Korea University Anam Hospital “The advantage of rosuvastatin is that it has the strongest ability to lower LDL cholesterol (LDL-C). Through the ASTEROID study, it was also demonstrated for the first time that it is a statin capable of regressing the volume of intravascular atherosclerotic plaques. In particular, early treatment with statins […]
The Importance of LDL Cholesterol Control and the Role of Statins in Cardiovascular Disease Prevention: A Focus on Korean Guidelines
The demand for powerful drugs to control LDL cholesterol levels in high-risk cardiovascular disease groups continues to increase as the target level of LDL cholesterol control declines. Statins have been the mainstay of treatment in clinical practice thus far, as they have met the needs of LDL cholesterol control. The ‘LDL theory’ supports the need […]
Hanmi “Rosuzet is excellent for controlling LDL-C in patients who have had stent implantation”
[메디칼업저버 손형민 기자] Hanmi Pharmaceutical announced on the 25th that the third sub-analysis result of the Rosuzet study (ingredient name Rosuvastatin∙ezetimibe) was recently listed in ‘eClinicalMedicine’ (IF: 17.033), a sister journal of the world-renowned international academic journal The Lancet (IF: 202.731). Since the large-scale clinical ‘Race Study’ using Rosuzet was listed in The Lancet in […]
“Rosuzet is also excellent for controlling ‘LDL-C’ in stent patients”
Hanmi Pharmaceutical announced on the 25th that the results of the third sub-analysis of the Rosujet race study were recently published in ‘eClinicalMedicine (IF 17.033)’, the sister journal of the world-renowned international academic journal The Lancet. This sub-analysis was led by Professor Beomki Hong, Jungseon Kim, and Seungjun Lee, who are members of the Department […]
